Multiple outlets reported that President Donald Trump plans to nominate Heidi Overton to lead the FDA as commissioner. If confirmed, Overton would take over a regulator that has been without a permanent leader since Marty Makary resigned earlier in the year, with interim leadership handled by Kyle Diamantas. Overton, a physician and White House policy aide, is reported to have previously served as chief policy officer for the America First Policy Institute and has been associated with vaccine and regulatory flexibility debates. Investors and industry analysts cited uncertainty about her impact on biopharma policy and drug review processes given her limited direct regulatory experience. The nomination comes as the FDA faces renewed scrutiny around independence and agency decision-making, setting up a high-stakes Senate confirmation process for drugmakers and healthcare stakeholders.